{"id":"bta-c585-oral-capsule","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"BTA-C585 is a small-molecule antiviral compound in development by Biota Pharma Europe Limited. While specific molecular details are limited in public literature, the compound is designed to interfere with viral replication machinery. The drug is being evaluated in Phase 2 clinical trials for antiviral indications.","oneSentence":"BTA-C585 is an oral antiviral agent that inhibits viral replication through targeting of viral proteases or polymerases.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:06:11.396Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Viral infection (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT02668367","phase":"PHASE1","title":"Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers","status":"COMPLETED","sponsor":"Biota Pharmaceuticals, Inc.","startDate":"2015-11","conditions":"Pharmacokinetics, Healthy Volunteers","enrollment":36},{"nctId":"NCT02718937","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study","status":"COMPLETED","sponsor":"Biota Pharma Europe Limited","startDate":"2016-03","conditions":"Respiratory Syncytial Virus (RSV) Infection","enrollment":60},{"nctId":"NCT02558413","phase":"PHASE1","title":"Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers","status":"COMPLETED","sponsor":"Biota Pharmaceuticals, Inc.","startDate":"2015-08","conditions":"Pharmacokinetics, Healthy Volunteers","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":243,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BTA585"],"phase":"phase_2","status":"active","brandName":"BTA-C585 oral capsule","genericName":"BTA-C585 oral capsule","companyName":"Biota Pharma Europe Limited","companyId":"biota-pharma-europe-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BTA-C585 is an oral antiviral agent that inhibits viral replication through targeting of viral proteases or polymerases. Used for Viral infection (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}